EP 1509235 A1 20050302 - METHOD FOR THE PROTECTION OF ENDOTHELIAL AND EPITHELIAL CELLS DURING CHEMOTHERAPY
Title (en)
METHOD FOR THE PROTECTION OF ENDOTHELIAL AND EPITHELIAL CELLS DURING CHEMOTHERAPY
Title (de)
METHODE ZUM SCHUTZ DER ENDOTHEL- UND EPITHELZELLEN WÄHREND DER CHEMOTHERAPIE
Title (fr)
PROCEDE POUR PROTEGER LES CELLULES ENDOTHELIALES ET EPITHELIALES AU COURS D'UNE CHIMIOTHERAPIE
Publication
Application
Priority
- EP 0305753 W 20030602
- US 38411402 P 20020531
- US 38743802 P 20020611
Abstract (en)
[origin: WO03101468A1] The present invention is directed to the use of a protective oligodeoxyribonucleotide for the treatment of a patient undergoing treatment with an immunosupressant. The invention is further directed to a pharmaceutical composition containing a therapeutically effective dose of an immunosuppressant and of a protective oligodeoxyribonucleotide.
IPC 1-7
IPC 8 full level
A61K 47/26 (2006.01); A61K 31/17 (2006.01); A61K 31/198 (2006.01); A61K 31/522 (2006.01); A61K 31/664 (2006.01); A61K 31/675 (2006.01); A61K 31/7076 (2006.01); A61K 31/7088 (2006.01); A61P 35/00 (2006.01); A61P 37/06 (2006.01)
CPC (source: EP)
A61K 31/198 (2013.01); A61K 31/522 (2013.01); A61K 31/675 (2013.01); A61K 31/7076 (2013.01); A61K 31/7088 (2013.01); A61P 35/00 (2017.12); A61P 37/06 (2017.12); A61P 39/00 (2017.12)
C-Set (source: EP)
Citation (search report)
See references of WO 03101468A1
Citation (examination)
- EISSNER G. ET AL: "Oligotide, a defibrotide derivative, protects human microvascular endothelial cells against fludarabine-induced activation, damage and allogenicity", BONE MARROW TRANSPLANTATION, vol. 35, 2005, pages 915 - 920
- LAZARUS H.M. ET AL.: "Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation", CANCER, vol. 49, no. 9, 1 May 1982 (1982-05-01), pages 1789 - 1795
- ERICHSEN C. ET AL: "Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma", JOURNAL OF SURGICAL ONCOLOGY, vol. 27, no. 4, December 1984 (1984-12-01), pages 268 - 270
- READ A.E. ET AL: "Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy", ANNALS OF INTERNAL MEDICINE, vol. 104, no. 5, May 1986 (1986-05-01), pages 651 - 655
- VOGELZANG N.J. ET AL: "Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer", ANNALS OF INTERNAL MEDICINE, vol. 95, no. 3, September 1981 (1981-09-01), pages 288 - 292
- SCHEULEN M.E. ET AL: "Raynaud's phenomenon and cancer chemotherapy", ANNALS OF INTERNAL MEDICINE, vol. 96, no. 2, February 1982 (1982-02-01), pages 256 - 257
- BRADA M. ET AL: "treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin", CANCER TREATMENT REPORTS, vol. 71, no. 6, June 1987 (1987-06-01), pages 655 - 656
- GRINER P.F. ET AL: "Veno-occlusive disease of the liver after chemotherapy of acute leukemia", ANNALS OF INTERNAL MEDICINE, vol. 85, no. 5, November 1976 (1976-11-01), pages 578 - 582
- GILL R.A. ET AL: "Hepatic veno-occlusive disease caused by 6-thioguanine", ANNALS OF INTERNAL MEDICINE, vol. 96, no. 1, January 1982 (1982-01-01), pages 58 - 60
- BEAUCHAMP M.H. ET AL: "Role of thromboxane in retinal microvascular degeneration in oxygen-induced retinopathy", JOURNAL OF APPLIED PHYSIOLOGY, vol. 90, no. 6, June 2001 (2001-06-01), pages 2279 - 2288
- GREENBERG H.S. ET AL: "Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system", JOURNAL OF NEUROSURGERY, vol. 61, no. 3, September 1984 (1984-09-01), pages 423 - 429
- GREENBERG H.S. ET AL: "Intra-arterial BCNU chemotherapy for the treatment of malignant gliomas of the central nervous system: a preliminary report", CANCER TREATMENT REPORTS, vol. 65, no. 9-10, September 1981 (1981-09-01), pages 803 - 810
- MARKS C.R. ET AL: "Small-vessel vasculitis and methotrexate", ANNALS OF INTERNAL MEDICINE, vol. 100, no. 6, June 1984 (1984-06-01), pages 916
- DE WYS W.D. ET AL: "Report of vasculitis and blindness after intracarotid injection of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in dogs", CANCER CHEMOTHERAPY REPORTS, vol. 57, no. 1, February 1973 (1973-02-01), pages 33 - 40
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 03101468 A1 20031211; AU 2003238189 A1 20031219; CA 2487171 A1 20031211; CN 1304011 C 20070314; CN 1655801 A 20050817; EA 008213 B1 20070427; EA 200401448 A1 20050630; EP 1509235 A1 20050302; HR P20041213 A2 20060430; IL 165353 A0 20060115; IS 7548 A 20041124; JP 2005527636 A 20050915; MX PA04011941 A 20050726; NO 20045655 L 20041227; NZ 536864 A 20080829; PL 374402 A1 20051017; RS 102504 A 20061215; UA 83628 C2 20080811
DOCDB simple family (application)
EP 0305753 W 20030602; AU 2003238189 A 20030602; CA 2487171 A 20030602; CN 03812501 A 20030602; EA 200401448 A 20030602; EP 03735516 A 20030602; HR P20041213 A 20041227; IL 16535304 A 20041123; IS 7548 A 20041124; JP 2004508823 A 20030602; MX PA04011941 A 20030602; NO 20045655 A 20041227; NZ 53686403 A 20030602; PL 37440203 A 20030602; UA 20041109654 A 20030602; YU P102504 A 20030602